Global Extracorporeal Carbon Dioxide Removal (ECCO2R) Devices Market to Grow at a CAGR of 6.9% During the Period 2024-2032, Driven by Need to Treat Respiratory Failure

The global extracorporeal carbon dioxide removal (ECCO2R) devices market is likely to be driven by the need to treat conditions of respiratory failure. In recent years, new-generation extracorporeal carbon dioxide removal (ECCO2R) devices have been developed. More efficient venovenous (VV-ECCO2R) devices have become available and replaced the arteriovenous approach, with the advantage of not needing arterial puncture. These devices offer lower resistance to blood flow, have small priming volumes, and offer a significantly more efficient gas exchange with comparatively low extracorporeal blood flows (0.4–1 L/min). With extracorporeal carbon dioxide removal (ECCO2R) the patient’s PaCO2 is chiefly determined by the rate of fresh gas flow through the membrane lung. Significant technical advancements have improved extracorporeal techniques for carbon dioxide removal; such changes may help avoid worsening respiratory failure and respiratory acidosis, and possibly prevent or reduce the duration of IMV in patients with aggravation of COPD and asthma. North America, Europe and Asia are expected to be key markets.

Companies are engaged in providing modern solutions. For example, in 2021, Baxter International Inc. announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 was devised to help simplify administration of continuous renal replacement therapy (CRRT) and other organ support therapies, while offering hospitals the flexibility to fulfil the unique demands of the intensive care unit (ICU). The PrisMax 2 system featured new solutions within the company’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger that delivered extracorporeal carbon dioxide removal (ECCO2R) therapy to support the management of acute respiratory dysfunction. PrisMax 2 and TrueVue were soon to be available in over 20 countries across the United States and Europe. Such developments are expected to drive the global extracorporeal carbon dioxide removal (ECCO2R) devices market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In 2020, it was reported that US FDA had granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for individuals with acute lung failure or acute cardiopulmonary failure. With class II approval, the Novalung system was the first complete system approved for ECMO therapy (ECMO = extracorporeal membrane oxygenation) and long-term use for a duration of over six hours. Additionally, the Novalung system could be used to apply extracorporeal CO2 removal (ECCO2R) for severe lung diseases. The whole system comprised the Novalung console and the XLung kit.

PROLUNG® is a minimally invasive extracorporeal carbon dioxide removal (ECCO2R) system. The low flow extracorporeal CO2 elimination system uses a conventional 13 Fr catheter, which enables improvement of hypercapnia in patients with ARDS, exacerbation of COPD, minimization of risk in lung transplantation, help in reduction of CO2 in cranio-encephalic trauma and acceleration of healing in tissue injuries, thanks to the possibility of reducing volume and pressure in ventilation.

Key Findings of the Report:

• The global extracorporeal carbon dioxide removal (ECCO2R) devices market is expected to be driven by the need to manage cases of respiratory failure. 

• Technological advancements are expected to drive market growth.

• North America, Europe and Asia are projected to be key markets.

Market Analysis by Product, Access, End Use, Application, and Region:

• By product, the market is classified into Disposables, Extracorporeal CO2 Machines, and Others.

• By access, the market is segmented into Venovenous and Arteriovenous.

• By end use, the market is classified into Ambulatory Surgical Centres, Hospitals, Clinics, and Others.

• By application, the market is divided into Chronic Obstructive Pulmonary Disease (COPD), Bridge to Lung Transplant, Acute Respiratory Distress Syndrome (ARDS), and Others.

• By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.